Pancreatic Function Tests

Overview And Pathophysiology

• Assess exocrine pancreatic insufficiency (EPI).
• Normal pancreas possesses massive reserve capacity.
• Clinical steatorrhea and severe malabsorption manifest only after 90-98% destruction of acinar cell mass.
• Categorized primarily into direct (stimulatory) and indirect (non-stimulatory) tests.

Indirect Pancreatic Function Tests

• Measure downstream consequences of malabsorption or quantify specific pancreatic enzymes in stool, blood, or breath.
• Preferred for initial screening; highly sensitive for moderate-to-severe EPI; exhibits low sensitivity for mild disease.

Fecal Elastase-1 (FE-1)

• Most commonly utilized non-invasive screening test.
• Employs monoclonal enzyme-linked immunosorbent assay (ELISA).
• Detects human chymotrypsin-like elastases (CELA) 3A and 3B, resisting intestinal degradation.
• Advantages: Unaffected by exogenous porcine pancreatic enzyme replacement therapy (PERT). Requires single small stool sample (>1 gram). Stable at room temperature for weeks.
• Interpretation:
  • > 200 ug/g: Normal pancreatic function.
  • 100-200 ug/g: Intermediate/mild dysfunction.
  • <100 ug/g: Diagnostic for severe EPI.
• Limitations: Yields falsely low results in dilute, watery stools (infectious diarrhea, short bowel syndrome, ileostomy output).

72-Hour Fecal Fat Excretion (Coefficient Of Fat Absorption)

• Gold standard for diagnosing fat malabsorption.
• Involves strict 3-day stool collection paired with exact dietary fat intake recall.
• Formula:

• Interpretation: Normal CFA >85% (infants <6 months); >93-95% (older children and adults).
• Limitations: Cumbersome, unpleasant processing. Cannot differentiate pancreatic insufficiency from intestinal mucosal diseases (e.g., celiac disease).

Serum Immunoreactive Trypsinogen (IRT)

• Measures cationic trypsinogen escaping into bloodstream from damaged pancreas.
• Clinical Utility:
  • Newborn screening for cystic fibrosis: Markedly elevated at birth due to ductal obstruction.
  • Declines progressively as pancreatic acinar mass undergoes fibrotic destruction over time.
  • Levels <20 ng/mL specific for established EPI.
  • Evaluates pancreatic phenotype in Shwachman-Diamond syndrome (low levels in children <3 years).
• Limitations: Normal levels do not effectively rule out EPI.

13C-Labeled Mixed-Triglyceride Breath Test (13C-MTG)

• Non-invasive assessment of in-vivo lipase activity.
• Orally administered 13C-labeled triglycerides undergo digestion by pancreatic lipase; resulting free fatty acids absorb and oxidize in liver.
• Measured via exhaled 13CO2.
• Limitations: Limited availability. Difficult for young children to perform. Influenced by concurrent liver disease, lung disease, and delayed gastric emptying.

Fecal Chymotrypsin

• Less sensitive and specific exocrine marker.
• Cross-reacts with porcine enzymes; utilized primarily to monitor PERT compliance in established EPI.

Direct Pancreatic Function Tests

• Evaluate direct acinar and ductal secretory capacity.
• Utilize intravenous secretagogues: cholecystokinin (CCK) (stimulates acinar enzyme secretion) and/or secretin (stimulates ductal fluid/bicarbonate secretion).

Test Modalities

• Endoscopic Pancreatic Function Testing (ePFT):
  • Intravenous secretin/CCK administered.
  • Duodenal fluid aspirated endoscopically after 10 minutes. Fluid analyzed for volume, pH, bicarbonate, and enzymes. Bicarbonate <80 mmol/L indicates exocrine insufficiency.
• Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (MR PFT):
  • Non-invasive, radiation-free alternative quantifying fluid output and ductal morphology.
  • Pediatric standardization and protocols remain pending.

Clinical Utility And Limitations

• Gold standard for precise exocrine function assessment.
• High sensitivity and specificity; detects early, mild chronic pancreatitis before overt steatorrhea develops.
• Disadvantages: Invasive, expensive, technically challenging. Requires sedation or general anesthesia. Lacks standardized pediatric protocols. False abnormalities possible in diabetes, celiac sprue, or advanced liver disease.

Comparative Summary